P27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas

Oral Oncology

Volumn 50, Issue 2, 2014, Pages 128-134

  Moreno Galindo, Carla ^a   Hermsen, Mario ^a   García Pedrero, Juana M ^a   Fresno, Manuel F ^a   Suárez, Carlos ^a   Rodrigo, Juan P ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

Author keywords

5 Fluorouracil; Biomarkers; Chemotherapy response; Cisplatin; Head and neck cancer; Immunohistochemistry; Outcome; Squamous cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CISPLATIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; FEMALE; HUMAN; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

5-FLUOROURACIL; BIOMARKERS; CHEMOTHERAPY RESPONSE; CISPLATIN; HEAD AND NECK CANCER; IMMUNOHISTOCHEMISTRY; OUTCOME; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CISPLATIN; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; FLUOROURACIL; HUMANS; HYPOPHARYNGEAL NEOPLASMS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891835032     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.10.018     Document Type: Article

References (52)

1. S. Marur, G. D'Souza, W.H. Westra, and A.A. Forastiere HPV-associated head and neck cancer: a virus-related cancer epidemic Lancet Oncol 11 2010 781 789
2. R.J. Young, D. Rischin, R. Fisher, G.A. McArthur, S.B. Fox, and L.J. Peters et al. Relationship between epidermal growth factor receptor status, p16INK4A, and outcome in head and neck squamous cell carcinoma Cancer Epidemiol Biomarkers Prev 20 2011 1230 1237
3. Y. Xiong, G.J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach P21 is a universal inhibitor of cyclin kinases Nature 366 1993 701 704
4. I.M. Chu, L. Hengst, and J.M. Slingerland The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy Nat Rev Cancer 8 2008 253 267
5. R. Donnellan, and R. Chetty Cyclin D1 and human neoplasia Mol Pathol 51 1998 1 7
6. K.H. Vousden, and D.P. Lane P53 in health and disease Nat Rev Mol Cell Biol 8 2007 275 283
7. Y. Tsujimoto, J. Cossman, E. Jaffe, and C.M. Croce Involvement of the bcl-2 gene in human follicular lymphoma Science 228 1985 1440 1443
8. S. Kalyankrishna, and J.R. Grandis Epidermal growth factor receptor biology in head and neck cancer J Clin Oncol 24 2006 2666 2672
9. M. Osaki, M. Oshimura, and H. Ito PI3K-Akt pathway: its functions and alterations in human cancer Apoptosis 9 2004 667 676
10. G.L. Semenza HIF-1 and tumour progression: pathophysiology and therapeutics Trends Mol Med 8 2002 S62 S67
11. A.L. Harris Hypoxia - a key regulatory factor in tumour growth Nat Rev Cancer 2 2002 38 47
12. H. Sharma, S. Sen, L. Lo Muzio, A. Mariggiò, and N. Singh Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy Cancer Biol Ther 4 2005 720 727
13. S. Urba, G. Wolf, A. Eisbruch, F. Worden, J. Lee, and C. Bradford et al. Single-cycle induction chemotherapy select patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm J Clin Oncol 24 2006 593 598
14. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
15. R. Cabanillas, J.P. Rodrigo, P. Secades, A. Astudillo, C.S. Nieto, and M.D. Chiara et al. The relation between hypoxia-inducible factor (HIF)-1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer J Surg Oncol 99 2009 373 378
16. M.A. Wildeman, J.H. Gibcus, M. Hauptmann, A.C. Begg, M.L. van Velthuysen, and F.J. Hoebers et al. Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response? Laryngoscope 119 2009 316 322
17. CIP1/WAF1) protein accumulation in head-and-neck cancer Int J Cancer 74 1997 383 389
18. N. Kapranos, G.P. Stathopoulos, L. Manolopoulos, E. Kokka, C. Papadimitriou, and A. Bibas et al. P53, p21 and p27 protein expression in head and neck cancer and their prognostic value Anticancer Res 21 2001 521 528
19. C.A. Fischer, M. Jung, I. Zlobec, E. Green, C. Storck, and L. Tornillo et al. Co-overexpression of p21 and Ki-67 in head and neck squamous cell carcinoma relative to a significantly poor prognosis Head Neck 33 2011 267 273
20. H. Korkmaz, W. Du, G.H. Yoo, I.I. Enamorado, H.S. Lin, and V. Adsay et al. Prognostic significance of G1 cell-cycle inhibitors in early laryngeal cancer Am J Otolaryngol - Head Neck Med Surg 26 2005 77 82
21. W.M. Ongkeko, X. Altuna, R.A. Weisman, and J. Wang-Rodriguez Expression of protein tyrosine kinases in head and neck squamous cell carcinomas Am J Clin Pathol 124 2005 71 76
22. T. Taguchi, Y. Kato, Y. Baba, G. Nishimura, Y. Tanigaki, and C. Horiuchi et al. Protein levels of p21, p27, cyclin E and bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas Oncol Rep 11 2004 421 426
23. D. Lai, S. Visser-Grieve, and X. Yang Tumour suppressor genes in chemotherapeutic drug response Biosci Rep 32 2012 361 374
24. G. Esposito, S. Pucciarelli, R. Alaggio, L. Giacomelli, E. Marchiori, and G.A. Iaderosa et al. P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer Ann Surg Oncol 8 2001 311 318
25. M. Cuadrado, P. Gutierrez-Martínez, A. Swat, A.R. Nebreda, and O. Fernández-Carpetillo P27kip1 stabilization is essential for the maintenance of cell cycle arrest in response to DNA damage Cancer Res 69 2009 8726 8732
26. N. Reimers, H.U. Kasper, S.J. Weissenborn, H. Stützer, S.F. Preuss, and T.K. Hoffmann et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer Int J Cancer 120 2007 1731 1738
27. B. Kumar, K.G. Cordell, J.S. Lee, F.P. Worden, M.E. Prince, and H.H. Tran et al. EGFR, p16, HPV titer, bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer J Clin Oncol 26 2008 3128 3137
28. W.S. Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, and J.M. Trent et al. WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
29. J.W. Harper, G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases Cell 75 1993 805 816
30. Z. Yu, P.M. Weinberger, B.G. Haffty, C. Sasaki, C. Zerillo, and J. Joe et al. Cyclin D1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma Clin Cancer Res 11 2005 1160 1166
31. P. Zhang, Z. Zhang, X. Zhou, W. Qiu, F. Chen, and W. Chen Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line BMC Cancer 6 2006 224
32. X. Zhou, Z. Zhang, X. Yang, W. Chen, and P. Zhang Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity Int J Cancer 124 2009 483 489
33. Z. Feng, W. Guo, C. Zhang, Q. Xu, P. Zhang, and J. Sun et al. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma PLoS ONE 6 2011 e26399
34. P. Nix, L. Cawkwell, H. Patmore, J. Greenman, and N. Stafford Bcl-2 expression predicts radiotherapy failure in laryngeal cancer Br J Cancer 92 2005 2185 2189
35. L.T. Condon, J.N. Ashman, S.R. Ell, N.D. Stafford, J. Greenman, and L. Cawkwell Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance Int J Cancer 100 2002 472 475
36. P. Fouret, S. Temam, F. Charlotte, and J. Lacau-St-Guily Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck Br J Cancer 87 2002 1390 1395
37. D.K. Trask, G.T. Wolf, C.R. Bradford, S.G. Fisher, K. Devaney, and M. Johnson et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation Laryngoscope 112 2002 638 644
38. S. Casado, J. Forteza, S. Dominguez, M.T. Abad, I. Perez, and I. Intxaurbe et al. Predictive value of P53, BCL-2, and BAX in advanced head and neck carcinoma Am J Clin Oncol 25 2002 588 590
39. W.A. Michaud, A.C. Nichols, E.A. Mroz, W.C. Faquin, J.R. Clark, and S. Begum et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma Clin Cancer Res 15 2009 1645 1654
40. N.N. Danial, and S.J. Korsmeyer Cell death: critical control points Cell 23 116 2004 205 219
41. W.S. Tsai, W.S. Yeow, A. Chua, R.M. Reddy, D.M. Nguyen, and D.S. Schrump et al. Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin Mol Cancer Ther 5 2006 2977 2990
42. C.R. Bradford, S. Zhu, G.T. Wolf, J. Poore, S.G. Fisher, and T. Beals et al. Over expression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group Otolaryngol Head Neck Surg 113 1995 408 412
43. C.R. Bradford, S. Zhu, H. Ogawa, T. Ogawa, M. Ubell, and A. Narayan et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines Head Neck 25 2003 654 661
44. B. Kumar, K.G. Cordell, N. D'Silva, M.E. Prince, M.E. Adams, and S.G. Fisher et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer Arch Otolaryngol Head Neck Surg 134 2008 363 369
45. S. Temam, A. Flahault, S. Perie, G. Monceaux, F. Coulet, and P. Callard et al. P53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck J Clin Oncol 18 2000 385 394
46. K.K. Ang, B.A. Berkey, X. Tu, H.Z. Zhang, R. Katz, and E.H. Hammond et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 2002 7350 7356
47. S.M. Bentzen, B.M. Atasoy, F.M. Daley, S. Dische, P.I. Richman, and M.I. Saunders et al. Epidermal growth factor receptor expression in pre-treatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a trial J Clin Oncol 23 2005 5560 5567
48. G. Numico, E.G. Russi, I. Colantonio, R.A. Lantermo, N. Silvestris, and R. Vitiello et al. EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy Anticancer Res 30 2010 671 676
49. J. LoPiccolo, C.A. Granville, J.J. Gills, and P.A. Dennis Targeting Akt in cancer therapy Anticancer Drugs 18 2007 861 874
50. S.Y. Nam, G.A. Jung, G.C. Hur, H.Y. Chung, W.H. Kim, and D.W. Seol et al. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers Cancer Sci 94 2003 1066 1073
51. G.B. Van den Broek, M. Wildeman, C.R. Rasch, N. Armstrong, E. Schuuring, and A.C. Begg et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation Int J Cancer 124 2009 2643 2650
52. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184